This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cramer's 'Mad Money' Recap: Next Week's Game Plan

Souki also explained that over the past six months America has increased its oil production by half a million barrels a day. With oil comes gas, he said, a commodity that many oil companies are simply burning off as they have no idea what to do with it. Meanwhile, in other parts of the globe, natural gas is fetching prices five times higher than in the U.S.

Among Souki's many import markets is Japan, a country that is closing its nuclear facilities and will need a replacement energy source. Souki said the first ships will begin leaving Louisiana with U.S. natural gas by 2015.

Cramer said despite many skeptics, Souki was able to pull this project together, making shareholders a lot of money in the process.

Get Ready to Speculate

For "Speculation Friday," Cramer highlighted Dynavax Technologies (DVAX - Get Report), a stock not for the faint of heart, but one with the potential to double in value.

Cramer explained that Dynavax has a promising drug to treat Hepatitis-B in late-stage clinical trials, one that's giving 91% of patients a successful result after just two shots compared to 81% of patients achieving the same after three shots for the current treatment. While the treatment is groundbreaking, Cramer said the FDA did approve a similar vaccine for cervical cancer, so there is precedent for a drug of this nature.

Cramer gave all of his usual caveats for investing in such a speculative name, one that could double on positive news but also get cut in half on a negative result. He said to do your homework, use limit orders and never chase the stock higher. There will be no new data points for Dynavax for the next six weeks, said Cramer, so there is no hurry to invest.

So how much of an opportunity is there for Dynavax? Cramer said the company is valued at just $800 million, but the market for Hep-B is currently $1.5 billion. Assuming sales of $700 million by 2018, Cramer said the stock is worth twice what it is today.

Lightning Round

Here's what Cramer had to say about callers' stocks during the "Lightning Round":

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
AAPL $125.70 -0.53%
DVAX $23.14 0.00%
GOOG $549.83 -0.40%
LNG $78.90 0.00%
FB $83.20 0.00%


DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs